🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,82 USD

Máx. histórico

178,74

2145 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,03%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,42%

Cierre anterior

17,57

Rango de hoy

17,52 – 18,77

Volumen hoy

2.596.193

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 17 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
10/06/2009 9,90 9,90 8,46 9,00 -8,54% 14,55% 148.167
09/06/2009 9,96 9,96 9,48 9,84 +1,86% 4,82% 66.650
08/06/2009 9,54 9,66 9,24 9,66 +1,26% 4,40% 112.233
05/06/2009 9,48 9,54 8,82 9,54 +1,92% 7,59% 115.333
04/06/2009 9,66 10,14 8,76 9,36 +2,63% 14,29% 266.483
03/06/2009 7,80 9,48 7,68 9,12 +16,92% 23,08% 354.683
02/06/2009 8,04 8,10 7,62 7,80 -0,76% 5,97% 62.933
01/06/2009 7,32 8,28 7,20 7,86 +7,38% 14,75% 158.300
29/05/2009 7,50 7,74 6,90 7,32 -3,94% 11,20% 109.517
28/05/2009 7,80 7,92 7,50 7,62 +0,79% 5,38% 78.650
27/05/2009 7,20 7,92 6,90 7,56 +6,78% 14,17% 160.050
26/05/2009 6,60 7,14 6,18 7,08 +8,26% 14,55% 220.883
22/05/2009 6,18 6,54 5,94 6,54 +5,83% 9,71% 74.783
21/05/2009 6,30 6,48 6,12 6,18 -2,83% 5,71% 63.617
20/05/2009 6,72 6,84 6,36 6,36 -3,64% 7,14% 75.350
19/05/2009 6,00 6,60 6,00 6,60 +10,00% 10,00% 98.533
18/05/2009 6,06 6,54 5,76 6,00 +0,00% 12,87% 177.867
15/05/2009 6,18 7,20 5,46 6,00 +0,00% 28,16% 336.400
14/05/2009 6,06 6,48 6,00 6,00 -3,85% 7,92% 69.833
13/05/2009 6,00 6,30 5,70 6,24 +1,96% 10,00% 114.083
12/05/2009 6,36 6,36 5,82 6,12 +3,03% 8,49% 195.417
11/05/2009 5,70 6,30 5,58 5,94 +11,24% 12,63% 200.600
08/05/2009 5,64 5,70 5,28 5,34 -3,26% 7,45% 90.783
07/05/2009 5,22 5,58 5,04 5,52 +6,98% 10,34% 105.567
06/05/2009 4,86 5,46 4,86 5,16 +10,26% 12,35% 190.650
05/05/2009 4,56 4,68 4,32 4,68 +2,63% 7,89% 70.233
04/05/2009 4,62 4,68 4,50 4,56 -5,00% 3,90% 85.117
01/05/2009 4,98 4,98 4,32 4,80 -1,23% 13,25% 140.017
30/04/2009 5,16 5,34 4,86 4,86 -5,81% 9,30% 111.733
29/04/2009 5,88 5,88 5,10 5,16 -12,24% 13,27% 143.550